A preclinical CRO specializing in animal models for obesity, Type 2 diabetes, and related comorbidities, including NASH, dyslipidemia, inflammation, fibrosis, diabetic nephropathy, neuropathy, HFpEF, and atherosclerosis. With over 20 years of experience, Physiogenex evaluates the efficacy of client drugs using gold-standard and radiotracer-based experiments in validated preclinical models.